Clinical Edge Journal Scan

High intensity interval training safe in PsA


 

Key clinical point: The 11-week high intensity interval training (HIIT) regimen had no influence on the bone marrow edema (BME) in patients with psoriatic arthritis (PsA).

Major finding: After 11 weeks, similar proportions of patients in the HIIT and control (no changes in exercise regimen) groups had BME changes, as assessed by a radiologist ( P = .5) and SpondyloArthritis Research Consortium of Canada scores ( P = 1). Although the values of 20 textural features were significantly different in the voxels of BME vs healthy bone marrow ( P < .001), the textural features of PsA lesions were similar between the HIIT and control groups ( P > .2).

Study details: Findings are from the analysis of a part of a randomized controlled trial including 37 patients with PsA who performed HIIT 3 times/week for 11 weeks or followed the control regimen and were evaluated by MRI.

Disclosures: This research was funded by Norwegian Extra Foundation for Health and Rehabilitation and Sør-Trøndelag University college. The authors declared no conflicts of interest.

Source: Chronaiou I et al. Evaluating the impact of high intensity interval training on axial psoriatic arthritis based on MR images. Diagnostics (Basel). 2022;12(6):1420 (Jun 8). Doi: 10.3390/diagnostics12061420

Recommended Reading

Questionnaire for patients with psoriasis might identify risk of axial involvement
MDedge Rheumatology
Rapid and sustained improvement in diverse PsA manifestations with guselkumab
MDedge Rheumatology
PsA: Long-term efficacy and safety of ixekizumab with or without csDMARD
MDedge Rheumatology
PsA: Sustained improvement in patient-reported outcomes with bimekizumab
MDedge Rheumatology
PsA: Risankizumab improves patient-reported outcomes in phase 3 trial
MDedge Rheumatology
Guselkumab leads to meaningful and consistent improvement in general health outcomes in PsA
MDedge Rheumatology
PsA: Long-term retention, efficacy, and safety of secukinumab in real world
MDedge Rheumatology
Reluctance of biologic initiation in systemic-therapy-naive PsA patients receiving apremilast
MDedge Rheumatology
PsA: Clinical and therapeutic features associated with early vs late onset of psoriasis
MDedge Rheumatology
Presence of PsA increases prevalence of anxiety and depression in psoriasis
MDedge Rheumatology